Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ERN1 | O75460 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196515 | 0.84 | LTA4H (0.52) | SNCALTA4HHDAC1KDM4EMAPT | |
| SCHEMBL4340111 | 0.83 | SNCA (0.59) | SNCACYP2E1CYP3A4CYP2A6CYP2C9 | |
| SCHEMBL498603 | 0.82 | DPP4 (0.53) | SNCALTA4HHDAC1KDM4EMAPT | |
| SCHEMBL4338418 | 0.81 | KCNH2 (0.58) | KCNH2LTA4HCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL4340693 | 0.80 | SNCA (0.46) | SNCAKCNH2LTA4HHDAC1ERN1 | |
| SCHEMBL1334676 | 0.79 | KCNH2 (0.48) | KCNH2LTA4HCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL14455886 | 0.79 | DPP4 (0.55) | KCNH2LTA4HCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL13144213 | 0.77 | CYP2E1 (0.44) | KCNH2LTA4HCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL15040942 | 0.77 | CYP2E1 (0.44) | KCNH2LTA4HCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL3143466 | 0.76 | DPP4 (0.47) | KCNH2LTA4HCYP2E1CYP3A4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531619-B2 | Process for producing dendrimer, building block compound, and process for producing thiophene compound | TOYO GOSEI CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1535942-B1 | METHOD FOR PRODUCING A ENDRIMER, BUILDING BLOCK COMPOUND, AND METHOD FOR PRODUCING A THIOPHENE COMPOUND | TOYO GOSEI CO LTD (JP) | 2007-04-11 | — | — | EP | disclosed |
| EP-1535942-B1 | METHOD FOR PRODUCING A ENDRIMER, BUILDING BLOCK COMPOUND, AND METHOD FOR PRODUCING A THIOPHENE COMPOUND | TOYO GOSEI CO LTD (JP) | 2007-04-11 | — | — | EP | disclosed |
| US-20060122364-A1 | Process for producing dendrimer, building block compound, and process for producing thiophene compound | TOYO GOSEI CO., LTD. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1535942-A1 | PROCESS FOR PRODUCING DENDRIMER, BUILDING BLOCK COMPOUND, AND PROCESS FOR PRODUCING THIOPHENE COMPOUND | Toyo Gosei Co., Ltd. (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122364-A1 | Process for producing dendrimer, building block compound, and process for producing thiophene compound | CCKBR, MVD, DRD4 | SNCA 1259/4885KCNH2 584/4885LTA4H 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.